We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vascular Endothelial Protection Effects of Dextromethorphan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00605605
Recruitment Status : Completed
First Posted : January 31, 2008
Last Update Posted : January 31, 2008
Sponsor:
Information provided by:
National Cheng-Kung University Hospital

Brief Summary:
To test the hypothesis that DM could have anti-inflammatory effect and thus achieve vascular protection effect on heavy smokers.

Condition or disease Intervention/treatment Phase
Atherosclerosis Smoking Inflammation Drug: Dextromethorphan Phase 4

Detailed Description:

Dextromethorphan (DM), an ingredient widely used in antitussive remedies, had been reported to reduce the inflammation-mediated degeneration of neurons. We recently found that DM can prevent vascular remodeling and neuron injury in animal models of carotid ligation and cerebral ischemia injuries, respectively. It was believed that its action was through the anti-oxidant and NADPH pathway to protect brain cells. However, the mechanism and actual effect on human vascular protection remained unclear.

To test the hypothesis that DM could have anti-inflammatory effect and thus achieve vascular protection effect on heavy smokers, this prospective study will be conducted to treat subjects with heavy smoking history with DM or not and evaluate the anti-inflammatory and the improvement of endothelial function.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Anti-Inflammation & Vascular Endothelial Protection Effects of Dextromethorphan on Heavy Smoker
Study Start Date : March 2005
Primary Completion Date : December 2005
Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: Dextromethorphan
120 mg/day, single once daily dose taken after breakfast by oral route
Other Name: medicon for DM



Primary Outcome Measures :
  1. Endothelial function [ Time Frame: 1, 2, 3 and 6 month ]

Secondary Outcome Measures :
  1. Surrogate end-points of the study: hs-CRP, sPLA2, matrix metalloproteinase-3, interleukin-6, tumor necrosis factor-alfa receptor II, GSH-Px, and urinary excretion of 8-PGF2alfa [ Time Frame: 1, 2, 3 and 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • healthy male volunteers who are currently smoking

Exclusion Criteria:

  • personal history of hypertension or diabetes mellitus
  • family history with
  • documented premature cardiovascular events
  • cardiovascular-associated sudden death
  • total cholesterol > 240 mg/dL
  • triglyceride > 200 mg/dL
  • low-density lipoprotein > 160 mg/dL.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00605605


Locations
Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan, 704
Sponsors and Collaborators
National Cheng-Kung University Hospital
Investigators
Principal Investigator: Ping-Yen Liu, MD, PhD Assiatant Professor of National Cheng Kung University Medical Center

Responsible Party: Ping-Yen Liu/ Assitant Professor, National Cheng-Kung University Medical Center
ClinicalTrials.gov Identifier: NCT00605605     History of Changes
Other Study ID Numbers: HR-93-28
91-B-FA09-2-4 grant number
First Posted: January 31, 2008    Key Record Dates
Last Update Posted: January 31, 2008
Last Verified: January 2008

Keywords provided by National Cheng-Kung University Hospital:
endothelial function
atherosclerosis
smoking
inflammation
antioxidant

Additional relevant MeSH terms:
Inflammation
Atherosclerosis
Pathologic Processes
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Dextromethorphan
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs